Pfizer Inc PFE

$29.58 +0.14 (0.48%)

Valuation

Market cap
168,596,352,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.65
Forward PE
9.99
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
28,627,400
Avg volume
33,309,836
Day's range
$29.42 – $29.74
Shares out
5,699,674,000
Stochastic %K
89%
Beta
0.32
Analysts
Sell
Price target
$29.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

DrMcSavage Oct 18, 12:40 AM
$PFE I don’t expect a Moderna type move but it can be significant
0 replies
zustrelaax Oct 17, 7:53 PM
$PFE $NVAX IDWeek 2026 runs Oct 21–24, and Pfizer is presenting 57 abstracts there, including 12 oral presentations with clinical milestones for its next-gen pediatric pneumococcal vaccine and registrational Lyme vaccine. Positive readouts would be a genuine catalyst. Any surprisre announcements will move it to the 35
2 replies
Samishere Oct 17, 4:17 PM 1 replies
BioTechHealthX Oct 17, 3:04 PM
$PFE Pfizer Inc. (NYSE: PFE) lifted its annual revenue guidance midpoint by $500 million. Explore its AI drug-discovery push and the pipeline hurdles investors should watch. https://biotechhealthx.com/biotech-news/pfizer-pfe-raises-its-revenue-outlook-by-500m-as-ai-enters-the-lab/
0 replies
SuperGreenToday Oct 17, 5:41 AM
$PFE Share Price: $29.57 Contract Selected: Nov 13, 2026 $30 Calls Buy Zone: $0.43 – $0.54 Target Zone: $0.71 – $0.86 Potential Upside: 54% ROI Time to Expiration: 27 Days | Updates via https://fxcapta.com/stockinfo/
0 replies
zustrelaax Oct 17, 12:07 AM
$PFE given market chaos perfect time to release a pr as this is a safe place and squeeze it to 35+
0 replies
mrwmrw999 Oct 17, 12:02 AM
$PFE I think PFE needs to buy Vaxart, dominate the next generation vaccine field.
3 replies
MrPeanutEsquire Oct 16, 10:27 PM
$PFE That'll do pig, that'll do
0 replies